Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies (Q4998796)
From MaRDI portal
scientific article; zbMATH DE number 7370402
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies |
scientific article; zbMATH DE number 7370402 |
Statements
Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies (English)
0 references
9 July 2021
0 references
continuous endpoint
0 references
dichotomization
0 references
dose-ranging trials
0 references
phase II
0 references
nonparametric optimal benchmark
0 references
